Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 765179 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BI 765179 + pembrolizumab is an investigational combination therapy being studied for advanced cancers, especially advanced head and neck cancer. BI 765179 is a bispecific monoclonal antibody targeting CD137 (also known as 4-1BB or TNFRSF9) and fibroblast activation protein (FAP). Pembrolizumab is an established immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). This combination aims to boost antitumor immune responses by simultaneously stimulating T cell activation (via CD137) and countering immunosuppressive tumor stroma (via FAP), in addition to blocking the PD-1/PD-L1 pathway to enhance T-cell function. BI 765179 is developed by Boehringer Ingelheim, while pembrolizumab is developed by Merck. The combination is being evaluated in phase 1 trials in patients with advanced solid tumors, including head and neck cancer[1][4][5].
- Other names
- anti-CD137/anti-FAP bispecific antibody + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TNFRSF9 (CD137 extracellular domain)FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on BI 765179 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 765179 + pembrolizumab.